# RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

> **NCT05127590** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Ribon Therapeutics, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Advanced Squamous Non-Small Cell Lung Carcinoma

## Interventions

- **DRUG:** RBN-2397

## Key facts

- **NCT ID:** NCT05127590
- **Lead sponsor:** Ribon Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-15
- **Primary completion:** 2023-11
- **Final completion:** 2023-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05127590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05127590, "RBN-2397 in Combination With Pembrolizumab in Patients With SCCL". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05127590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*